NantHealth Appointed by Genomics England to Deliver Clinical Genomic Interpretation and Reporting Capabilities to Support 100K Genomes Project

June 04, 2015 06:56 AM Eastern Daylight Time

LONDON–(BUSINESS WIRE)–NantHealth, a high speed secure cloud-based information technology provider combining science and big data to transform healthcare, today announces its appointment by Genomics England to deliver the clinical interpretation and reporting of sequenced genomes for the much anticipated and coveted 100K Genomes Project.

NantHealth, will implement its sophisticated, fully automated NantOmics™ Analytics Platform software (NantContraster™) to deliver clinical genomic interpretation and reporting capabilities to support Genomics England’s 100K Genomes Project. The software will be used to rapidly transport (NantTransporter ™) and analyse raw data from sequenced genomes of consented patients and transform it into meaningful, actionable information, which can be provided both as printable reports and in interactive form, via NantHealth’s fast, dynamic and the mobile enabled NantCancer Genome Browser™. This clinical interpretation of sequenced data is powered by a sophisticated, web-based decision support tool that uses complex logic and well proven algorithms to optimise and enable clinical genomic research in real-time. The information can be displayed at increasingly in-depth views; from a whole genome level, which provides immediate confirmation of detected variants and individual genetic alterations that make each patient’s disease unique, to the single-base level, which allows for an in-depth view of each of the full three billion bases.

“The vision put forth by Genomics England perfectly dovetails with our own goal of delivering precision medicine for the benefit of every patient based on their individual genomic profile,” said Dr. Patrick Soon-Shiong, founder and CEO of NantHealth. “Since January of 2014, we have analysed more than 15,000 genome samples, representing the scale at which our NantOmics Analytics Platform can operate. We have built a significant knowledge base around these data that enhances the value of our platform, allowing each new sample to benefit from the genomic profiles of past samples and adding to the knowledge base for the benefit of future patients. It is this deep experience that will help to ensure this project is a resounding success. Indeed, we look forward to building a learning system with Genomics England that will pave the way for true genomic medicine to be delivered as part of everyday clinical practice accessible by all NHS Trusts.”

About NantHealth
NantHealth, a member of the NantWorks ecosystem of companies, is a healthcare transformational cloud-based IT company converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care, in the time of need, anywhere, anytime. NantHealth works to transform clinical delivery with actionable clinical intelligence at the moment of decision, enabling clinical discovery through real-time machine learning systems. The company’s technology empowers clinicians, patients and researchers to transcend the traditional barriers of today’s healthcare system. By converging molecular science, near real-time patient signal monitoring, computer science and big data technology, the NantHealth Clinical Operating System (cOS) platform empowers providers, patients, and commissioners to coordinate best care, monitor outcomes and control cost in real-time. This is the first system of its kind in healthcare, enabling 21st century coordinated care at a lower cost, enabling value-based population health management at a single patient level and at the population at large. For more information please visit www.nanthealth.co.uk

About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers medical diagnostics capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. NantOmics is the first molecular diagnostics company to pioneer an integrated approach to unearthing the genomic and proteomic variances that initiate and drive cancer, by analysing both normal and tumour cells from the same patient and following identified variances through from DNA to RNA to protein to drug. NantOmics has a highly scalable cloud-based infrastructure capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumour sample used for genomic analysis. For more information please visit www.nantomics.com.

About NantTransporter
Data transfer is one of the largest challenges associated with the analysis of sequencing data. NantOmics has designed an infrastructure capable of storing and processing thousands of genomes a day quickly and securely. Our NantTransporter software application enables secure transport of data directly from sequencing machines to NantOmics’s secure private genome processing cloud. Data streams are encrypted using 128-bit Advanced Encryption Standard (AES-128), the same algorithms designated for Top Secret government documents. Initiating a transfer is as easy as obtaining a transfer code from our web site, and specifying the files to be sent. Annotation of the genomes begins immediately with no downtime between transferring and the beginning of processing.

NantWorks has built a dark fiber network capable of Tb/sec transfers between hospitals, academic institutions and sequencing centers. In July 2012 we demonstrated the capabilities of NantTransporter by transferring 94 TB of genomic data and achieved speeds of up to 9.55 Gb/sec with a sustained rate of over 8.232 Gb/sec, the fastest and largest documented transfer of genomic data to date. To date we have transported over 15,000 cancer genomes via NantTransporter.

About NantContraster
Accurately assessing the state of a patient’s genome is one of the most powerful tools in the emerging field of personalized medicine. NantOmics applies its leading, novel genomic analyses to rapidly discover variants in a patient’s raw genomics data using the latest sequencing technologies combined with advanced statistics and machine learning techniques.

NantContraster annotates all variants against a knowledge database comprising all known and probable disease-associated genes to rank the genomic alterations that have the highest clinical relevance. When applied to cancer tumor/normal samples, our analysis is capable of quickly identifying genomic alterations that could lead to tumorigenesis for a fraction of the cost of conventional approaches. NantContraster is capable of concurrently processing many samples to handle large workflows from researchers and hospital settings.

About NantCancer Genome Browser
NantOmics, NantCancer Genome Browser enables clinicians for the first time to investigate a tumor genome from the full three billion bases down to the single-base level in real-time, thanks to the power of the NantOmics supercomputing and secure mobile infrastructure. The Cancer Genome Browser integrates with NantHealth’s treatment recommendation engine, Eviti, to personalize treatment protocols and clinical trail selection to individual patients based on their genomic and transcriptomic signature. The NantCancer Genome Browser is fully encrypted to allow deployment in a HIPAA secured environment, enabling clinicians to securely access patient data as soon as it’s available, wherever they are.